These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Antiviral therapy in HBsAg-positive chronic liver disease (HBsAg+ve CLD): how many patients really need it?
    Author: Ascione A, Amitrano L, Riccio E, De Lella A, Canestrini C, de Bellis G, D'Alessandro R, Fiore R, Padulano P.
    Journal: Hepatogastroenterology; 1984 Jun; 31(3):123-4. PubMed ID: 6469200.
    Abstract:
    One hundred and seventy-one consecutive patients with HBsAg+ve CLD were investigated in order to assess whether they were actively replicating the hepatitis B virus, and therefore eligible for antiviral therapy. Our results show that only 5.8% of patients were actively replicating B virus and therefore antiviral therapy, when available, could be used only for a small subgroup of patients suffering from CLD due to hepatitis B virus chronic infection.
    [Abstract] [Full Text] [Related] [New Search]